Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

Description

GBI Researchs report, Women's Health Therapeutics Market to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in Menopause and Osteoporosis, provides in-depth analysis of unmet needs, drivers and barriers that impact the global womens health market. The report analyzes the markets for womens health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

Scope

The scope of this report includes:

• Annualized market data for the womens health market from 2001 to 2009, forecast forward to 2016.
• Analysis of the leading therapeutic segments, including osteoporosis, hormone therapy for menopause, endometriosis, womens infertility and polycistic ovarian syndrome.
• Analysis of the womens health market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
• Market characterization of the womens health market, including market size, annual cost of therapy, sales volume and treatment usage patterns.
• Key drivers and barriers that have a significant impact on the market.
• Coverage of pipeline molecules in various phases of drug development.
• Competitive benchmarking of leading companies. The key companies studied in this report are Merck, Pfizer, Johnson & Johnson, Teva Pharmaceuticals and Bayer-Schering Pharma.
• Key M&A activities, licensing agreements, that have taken place in 2009 in the global blood disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to

• Align your product portfolio to the markets with high growth potential.
• Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
• Develop key strategic initiatives by understanding the key focus areas of leading companies.
• Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Table of Contents

1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 7

2 Global WH Disorder Therapeutics Market:Introduction 10
2.1 GBI Research Report Guidance 10
3 Global WH Disorder Therapeutics Market: Market Characterization 11
3.1 Introduction 11
3.2 Revenue Forecasts for the Global WH Disorder Therapeutics Market 12
3.2.1 Sales Value 12
3.2.2 Annual Cost of Therapy 13
3.2.3 Treatment Usage Patterns 14
3.2.4 Generics Share in the Global WH Disorder Therapeutics Market 20

4 Global WH Disorder Therapeutics Market: Therapeutic Landscape 21
4.1 Global Menopause Therapeutics Market 21
4.1.1 Introduction 21
4.1.2 Sales Value 21
4.1.3 Annual Cost of Therapy 23
4.1.4 Treatment Usage Patterns 24
4.1.5 Drivers and Barriers for the Menopause Therapeutics Market 30
4.1.6 Market share by Geography 31
4.1.7 Product Analysis 33
4.2 Global Endometriosis Therapeutics Market 38
4.2.1 Introduction 38
4.2.2 Sales Value 39
4.2.3 Annual Cost of Therapy 40
4.2.4 Treatment Usage Patterns 41
4.2.5 Drivers and Barriers for the Endometriosis Therapeutics Market 46
4.2.6 Market share by Geography 47
4.2.7 Product Analysis 48
4.3 Global Postmenopausal Osteoporosis (PMO) Market 51
4.3.1 Introduction 51
4.3.2 Sales Value 52
4.3.3 Annual Cost of Therapy 53
4.3.4 Treatment Usage Patterns 54
4.3.5 Drivers and Barriers for the Menopause Therapeutics Market 60
4.3.6 Market Share by Geography 61
4.3.7 Product Analysis 63

5 Global WH Disorder Therapeutics Market: Geographical Landscape 68
5.1 Geographical Break-up 68
5.2 The US 71
5.2.1 Sales Value 71
5.2.2 Annual Cost of Therapy 72
5.2.3 Treatment Usage Patterns 73
5.3 Top Five Markets in Europe 78
5.3.1 Sales Value 78
5.3.2 Annual Cost of Therapy 79
5.3.3 Treatment Usage Patterns 80
5.4 Japan 85
5.4.1 Sales Value 85
5.4.2 Annual Cost of Therapy 86
5.4.3 Treatment Usage Patterns 87

6 Global WH Disorder Therapeutics Market: Pipeline Analysis 92
6.1 Introduction 92
6.1.1 Research and Development Pipeline Menopause 94
6.1.2 Research and Development Pipeline Endometriosis 96
6.1.3 Research and Development Pipeline - Postmenopausal Osteoporosis 98
6.2 Profiles of Key Late-Stage Drugs in the WH disorder Therapeutics Market 101
6.2.1 Aprela (Bazedoxifene/Conjugated Estrogen) 101
6.2.2 Pristiq (Desvenlaxafine, DVS-233) 102
6.2.3 Visanne 103
6.2.4 Elagolix (NBI-56418) 103
6.2.5 Odanacatib (MK-0822) 104
6.2.6 Viviant (Bazedoxifene) 105

7 Global WH Disorder Therapeutics Market: Competitive Landscape 106
7.1 Market Share Analysis: Womens Health 106
7.2 Competitive Profiling 108
7.2.1 Pfizer Inc 108
7.3 Eli Lilly and Company 109
7.4 Merck & Co. 110
7.5 Procter & Gamble Company 112
7.6 Hoffmann-La Roche Ltd. 114

8 Global WH Disorder Therapeutics Market: Strategic Consolidations 117
8.1 Mergers and Acquisitions 117
8.1.1 Overview 117
8.1.2 Ferring Pharmaceuticals Acquires Global Rights to LYSTEDA from Xanodyne Pharmaceuticals in May 2010 121
8.1.3 BioSante Acquires Elestrin Royalty from Azur Pharma in March 2010 121
8.1.4 Teva-KOWA Pharma Acquires Majority Stake in Taisho Pharmaceutical in February 2010 121
8.1.5 Sciele Pharma Acquires Addrenex Pharmaceuticals in November 2009 121
8.1.6 Warner Chilcott Acquires Prescription Drug Business of Procter & Gamble in October 2009 121
8.1.7 BioSante Pharmaceuticals Merges with Cell Genesys in October 2009 122
8.1.8 Hisamitsu Pharmaceutical Completes Acquisition Of Noven Pharmaceuticals in August 2009 122
8.1.9 Pfizer Acquires Wyeth in January 2009 122
8.1.10 Par Pharmaceuticals Acquires Assets Of Calcitonin & A Manufacturing Facility From MDRNA in April 2009 122
8.2 R&D Licensing Agreements 123
8.2.1 Deals by Indication 123
8.2.2 Deals by Phase 124
8.2.3 Deals by Geography 125

9 Global WH Disorder Therapeutics Market: Appendix 126
9.1 Market Definitions 126
9.2 Abbreviations 126
9.3 Coverage 128
9.3.1 Secondary Research 128
9.3.2 Primary Research 128
9.3.3 Forecasts 129
9.3.4 Expert Panel Validation 131
9.4 Contact Us 131
9.5 Disclaimer 131
9.6 Sources 132

List of Table:

Table 1: WH Disorder Therapeutics Market, Global, Sales Value ($bn), 20012009 12
Table 2: WH Disorder Therapeutics Market, Global, Sales Value ($bn), 20092016 13
Table 3: WH Disorder Therapeutics Market, Global, Annual Cost of Therapy ($), 20012009 13
Table 4: WH Disorder Therapeutics Market, Global, Annual Cost of Therapy ($), 20092016 14
Table 5: WH Disorder Therapeutics Market, Global, Treatment Usage Patterns (in millions), 20012009 15
Table 6: WH Disorder Therapeutics Market, Global, Treatment Usage Patterns (in millions), 20092016 15
Table 7: WH Disorder Therapeutics Market, Global, Menopause Sales Value ($bn), 20012009 22
Table 8: WH Disorder Therapeutics Market, Global, Menopause Sales Value ($bn), 20092016 22
Table 9: WH Disorder Therapeutics Market, Global, Menopause Annual Cost of Therapy ($), 20012009 23
Table 10: WH Disorder Therapeutics Market, Global, Menopause Annual Cost of Therapy ($), 20092016 23
Table 11: WH Disorder Therapeutics Market, Global, Menopause Treatment Usage Patterns (in millions), 20012009 25
Table 12: WH Disorder Therapeutics Market, Global, Menopause Treatment Usage Patterns (in millions), 20092016 25
Table 13: WH Disorder Therapeutics Market, Global, Endometriosis Sales Value ($bn), 20012009 39
Table 14: WH Disorder Therapeutics Market, Global, Endometriosis Sales Value ($bn), 20092016 39
Table 15: WH Disorder Therapeutics Market, Global, Endometriosis Annual Cost of Therapy ($), 20012009 40
Table 16: WH Disorder Therapeutics Market, Global, Endometriosis Annual Cost of Therapy ($), 20092016 40
Table 17: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Usage Patterns (in millions), 20012009 41
Table 18: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Usage Patterns (in millions), 20092016 42
Table 19: WH Disorder Therapeutics Market, Global, PMO Sales Value ($bn), 20012009 52
Table 20: WH Disorder Therapeutics Market, Global, PMO Sales Value ($bn), 20092016 52
Table 21: WH Disorder Therapeutics Market, Global, PMO Annual Cost of Therapy ($), 20012009 53
Table 22: WH Disorder Therapeutics Market, Global, PMO Annual Cost of Therapy ($), 20092016 54
Table 23: WH Disorder Therapeutics Market, Global, PMO Treatment Usage Patterns (in millions), 20012009 55
Table 24: WH Disorder Therapeutics Market, Global, PMO Treatment Usage Patterns (in millions), 20092016 55
Table 25: WH Disorder Therapeutics Market, Global, Sales Value by Geography ($bn), 20012009 69
Table 26: WH Disorder Therapeutics Market, Global, Sales Value by Geography ($bn), 20092016 69
Table 27: WH Disorder Therapeutics Market, The US, Sales Value ($bn), 20012009 71
Table 28: WH Disorder Therapeutics Market, The US, Sales Value ($bn), 20092016 71
Table 29: WH Disorder Therapeutics Market, The US, Annual Cost of Therapy ($), 20012009 72
Table 30: WH Disorder Therapeutics Market, The US, Annual Cost of Therapy ($), 20092016 72
Table 31: WH Disorder Therapeutics Market, The US, Treatment Usage Patterns (in millions), 20012009 73
Table 32: WH Disorder Therapeutics Market, The US, Treatment Usage Patterns (in millions), 20092016 74
Table 33: WH Disorder Therapeutics Market, Top Five Markets in Europe, Sales Value ($bn), 20012009 78
Table 34: WH Disorder Therapeutics Market, Top Five Markets in Europe, Sales Value ($bn), 20092016 78
Table 35: WH Disorder Therapeutics Market, Top Five Markets in Europe, Annual Cost of Therapy ($), 20012009 79
Table 36: WH Disorder Therapeutics Market, Top Five Markets in Europe, Annual Cost of Therapy ($), 20092016 79
Table 37: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Usage Pattern (in millions), 20012009 80
Table 38: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Usage Pattern (in millions), 20092016 81
Table 39: WH Disorder Therapeutics Market, Japan, Sales Value ($bn), 20012009 85
Table 40: WH Disorder Therapeutics Market, Japan, Sales Value ($bn), 20092016 85
Table 41: WH Disorder Therapeutics Market, Japan, Annual Cost of Therapy ($), 20012009 86
Table 42: WH Disorder Therapeutics Market, Japan, Annual Cost of Therapy ($), 20092016 86
Table 43: WH Disorder Therapeutics Market, Japan, Treatment Usage Pattern (in millions), 20012009 87
Table 44: WH Disorder Therapeutics Market, Japan, Treatment Usage Pattern (in millions), 20092016 88
Table 45: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Phase III Pipeline, August 2010 95
Table 46: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Phase II Pipeline, August 2010 95
Table 47: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Phase I Pipeline, August 2010 95
Table 48: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Preclinical Pipeline, August 2010 96
Table 49: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Phase III and Regulatory Filing, August 2010 97
Table 50: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Phase II Pipeline, August 2010 97
Table 51: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Phase I Pipeline, August 2010 97
Table 52: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Preclinical Pipeline, August 2010 97
Table 53: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Phase III and Regulatory Filing, August 2010 99
Table 54: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Phase II Pipeline, August 2010 99
Table 55: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Phase I Pipeline, August 2010 99
Table 56: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Preclinical Pipeline, August 2010 100
Table 57: WH Disorder Therapeutics Market, Global, Major M&A Deals, 20092010 120

List of Charts:

Figure 1: Womens Health Market, Global, Drivers and Restraints, 2009 11
Figure 2: WH Disorder Therapeutics Market, Global, Sales Value ($bn), 20012016 12
Figure 3: WH Disorder Therapeutics Market, Global, Annual Cost of Therapy ($), 20012016 13
Figure 4: WH Disorder Therapeutics Market, Global, Therapeutic Usage Patterns, 20012016 14
Figure 5: WH Disorder Therapeutics Market, Global, Diseased Population (in millions), 20012016 16
Figure 6: WH Disorder Therapeutics Market, Global, Treatment Seeking Population (in millions), 20012016 17
Figure 7: WH Disorder Therapeutics Market, Global, Diagnosed Population (in millions), 20012016 18
Figure 8: WH Disorder Therapeutics Market, Global, Prescription Population (in millions), 20012016 19
Figure 9: WH Disorder Therapeutics Market, Global, Branded v/s Generic Drugs, $bn, 20012016 20
Figure 10: WH Disorder Therapeutics Market, Global, Menopause Sales Value ($bn), 20012016 22
Figure 11: WH Disorder Therapeutics Market, Global, Menopause Annual Cost of Therapy ($), 20012016 23
Figure 12: WH Disorder Therapeutics Market, Global, Menopause Treatment Usage Patterns (million), 20012016 24
Figure 13: WH Disorder Therapeutics Market, Global, Menopause Diseased Population (in millions), 20012016 26
Figure 14: WH Disorder Therapeutics Market, Global, Menopause Treatment Seeking Population (in millions), 20012016 27
Figure 15: WH Disorder Therapeutics Market, Global, Menopause Diagnosis Population (in millions), 20012016 28
Figure 16: WH Disorder Therapeutics Market, Global, Menopause Prescription Population (in millions), 20012016 29
Figure 17: WH Disorder Therapeutics Market, Global, Menopause, Market Segmentation by Geography, 2009 and 2016 31
Figure 18: WH Disorder Therapeutics Market, Global, Menopause, Market Segmentation by Geography, 2001 - 2016 32
Figure 19: WH Disorder Therapeutics Market, Global, Endometriosis Sales Value ($bn), 20012016 39
Figure 20: WH Disorder Therapeutics Market, Global, Endometriosis Annual Cost of Therapy ($), 20012016 40
Figure 21: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Usage Patterns (million), 20012016 41
Figure 22: WH Disorder Therapeutics Market, Global, Endometriosis Diseased Population (in millions), 20012016 42
Figure 23: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Seeking Population (in millions), 20012016 43
Figure 24: WH Disorder Therapeutics Market, Global, Endometriosis Diagnosis Population (in millions), 20012016 44
Figure 25: WH Disorder Therapeutics Market, Global, Endometriosis Prescription Population (in millions), 20012016 45
Figure 26: WH Disorder Therapeutics Market, Global, Endometriosis, Market Segmentation by Geography, 2009 and 2016 47
Figure 27: WH Disorder Therapeutics Market, Global, Endometriosis, Market Segmentation by Geography, 2001 - 2016 48
Figure 28: WH Disorder Therapeutics Market, Global, PMO Sales Value ($bn), 20012016 52
Figure 29: WH Disorder Therapeutics Market, Global, PMO Annual Cost of Therapy ($), 20012016 53
Figure 30: WH Disorder Therapeutics Market, Global, PMO Treatment Usage Patterns (in millions), 20012016 54
Figure 31: WH Disorder Therapeutics Market, Global, PMO Diseased Population (in millions), 20012016 56
Figure 32: WH Disorder Therapeutics Market, Global, PMO Treatment Seeking Population (in millions), 20012016 57
Figure 33: WH Disorder Therapeutics Market, Global, PMO Diagnosis Population (in millions), 20012016 58
Figure 34: WH Disorder Therapeutics Market, Global, PMO Prescription Population (in millions), 20012016 59
Figure 35: WH Disorder Therapeutics Market, Global, PMO, Market Segmentation by Geography, 2009 and 2016 61
Figure 36: WH Disorder Therapeutics Market, Global, PMO, Market Segmentation by Geography, 20092016 62
Figure 37: WH Disorder Therapeutics Market, Global, Market Share by Geography, 2009 and 2016 68
Figure 38: WH Disorder Therapeutics Market, Global, Sales Value by Geography ($bn), 20012016 69
Figure 39: WH Disorder Therapeutics Market, Global, Geography Benchmarking, 2009 and 2016 70
Figure 40: WH Disorder Therapeutics Market, US, Sales Value ($bn), 20012016 71
Figure 41: WH Disorder Therapeutics Market, The US, Annual Cost of Therapy ($), 20012016 72
Figure 42: WH Disorder Therapeutics Market, The US, Treatment Usage Patterns (in millions), 20012016 73
Figure 43: WH Disorder Therapeutics Market, The US, Diseased Population (in millions), 20012016 74
Figure 44: WH Disorder Therapeutics Market, The US, Treatment Seeking Population (in millions), 20012016 75
Figure 45: WH Disorder Therapeutics Market, The US, Diagnosis Population (in millions), 20012016 76
Figure 46: WH Disorder Therapeutics Market, The US, Prescription Population (in millions), 20012016 77
Figure 47: WH Disorder Therapeutics Market, Top Five Markets in Europe, Sales Value ($bn), 20012016 78
Figure 48: WH Disorder Therapeutics Market, Top Five Markets in Europe, Annual Cost of Therapy ($), 20012016 79
Figure 49: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Usage Patterns (in millions), 20012016 80
Figure 50: WH Disorder Therapeutics Market, Top Five Markets in Europe, Diseased Population (in millions), 20012016 81
Figure 51: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Seeking Population (in millions), 20012016 82
Figure 52: WH Disorder Therapeutics Market, Top Five Markets in Europe, Diagnosis Population (in millions), 20012016 83
Figure 53: WH Disorder Therapeutics Market, Top Five Markets in Europe, Prescription Population (in millions), 20012016 84
Figure 54: WH Disorder Therapeutics Market, Japan, Sales Value ($m), 20012016 85
Figure 55: WH Disorder Therapeutics Market, Japan, Annual Cost of Therapy ($), 20012016 86
Figure 56: WH Disorder Therapeutics Market, Japan, Treatment Usage Pattern (in millions), 20012016 87
Figure 57: WH Disorder Therapeutics Market, Japan, Diseased Population (in millions), 20012016 88
Figure 58: WH Disorder Therapeutics Market, Japan, Treatment Seeking Population (in millions), 20012016 89
Figure 59: WH Disorder Therapeutics Market, Japan, Diagnosed Population (in millions), 20012016 90
Figure 60: WH Disorder Therapeutics Market, Japan, Prescription Population (in millions), 20012016 91
Figure 61: WH Disorder Therapeutics Market, Global, R&D Pipeline by Indication (%), August 2010 92
Figure 62: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase (%), August 2010 93
Figure 63: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market (%), August 2010 94
Figure 64: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in the Endometriosis Therapeutics Market (%), August 2010 96
Figure 65: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market (%), August 2010 98
Figure 66: WH Disorder Therapeutics Market, Global, Market Share of Top Manufacturers (%), 2009 106
Figure 67: WH Disorder Therapeutics Market, Global, Revenue of Top Five Players ($m), 2009 107
Figure 68: WH Disorder Therapeutics Market, Global, Average value, Revenue of Top Five Players ($m), 2009 107
Figure 69: WH Disorder Therapeutics Market, SWOT Analysis, Pfizer, 2009 109
Figure 70: WH Disorder Therapeutics Market, SWOT Analysis, Eli Lilly, 2009 110
Figure 71: WH Disorder Therapeutics Market, SWOT Analysis, Merck, 2009 111
Figure 72: WH Disorder Therapeutics Market, SWOT Analysis, Procter & Gamble, 2009 113
Figure 73: WH Disorder Therapeutics Market, SWOT Analysis, Hoffman-La Roche, 2009 116
Figure 74: WH Disorder Therapeutics Market, Global, M&A Deals by Indication (%), 2004-2010 117
Figure 75: WH Disorder Therapeutics Market, Global, M&A Deals by Deal Type (%), 2009 118
Figure 76: WH Disorder Therapeutics Market, Global, M&A Deals by Deal Value (%), 2009 119
Figure 77: WH Disorder Therapeutics Market, Global, Major Licensing Agreements By Indication (%), 20042010 123
Figure 78: WH Disorder Therapeutics Market, Global, Major Licensing Agreements By Phase (%), 20042010 124
Figure 79: WH Disorder Therapeutics Market, Global, Major Licensing Agreements By Geography (%), 20092010 125
Figure 80: GBI Research Market Forecasting Model, 2010 130

More Reports in Therapeutic Area

Bipolar Disorder Partnering 2007-2012


Clinical Lab Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles)


The Market for Home Care Products, 7th Edition


Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntingtons Disease Segment


World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)


Mental Illness Global Clinical Trials Review, Q1, 2011


Cardiac Rhythm Management (CRM) Market Report: 2011 Edition


Heart Valve Disease Global Clinical Trials Review, Q1, 2011


Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth


Dermatology Therapeutics Market to 2017 - Alopecia Market is Forecast to Decline Due to Patent Expiry of Finasteride in 2013 and Weak Pipeline

By This Publisher

Natural Gas Industry to 2017 - Depleting Conventional Crude Oil Reserves and Emerging Technologies in Gas Consumption Infrastructure Driving Growth


Crude Oil Industry to 2016 - Deepwater Discoveries Worldwide and Rising Industrial Demand in Emerging Economies Driving the Industry


Iron Ore Mining Market in Asia-Pacific to 2020 - Interplay Between Regional Demand for Steel and Iron Production Shapes the Competitive Landscape


Iron Ore Mining Market in North America to 2020 - Demand for Steel in the US to Boost Regional Iron Ore Production


Power Market in SAARC Countries to 2020 - FDI Driven by Private Sector Participation is Key to Future Growth


Oil and Gas Enhanced Production Services Industry to 2016 - Enhanced Oil Recovery (EOR) Driving E&P Activity in Depleting Hydrocarbon Reservoirs


Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments


Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules


Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion


Regulatory Intelligence on Medical Device Recalls - Ineffective Process Control, Defects in Design of Device, Software or Other Components are the Major Reasons for Recall